Baker & McKenzie and Clayton Utz are advising on the $691 million sale of Sydney-based iNova Pharmaceuticals Pty. Ltd. to Canadian drug company Valeant Pharmaceutical International, Inc.
Mississauga, Ontario-based Valeant is buying iNova from a consortium led by Australian private equity firms Ironbridge and Archer Capital. The Australian company’s leading brands including weight-loss drug Duromine and cold medicines Difflam and Duro-Tuss, which are distributed throughout Asia, Australia, and South Africa.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
